Author:
Li Xia,Yan Xiao,Guo Wenjian,Huang Xin,Huang Jiansong,Yu Mengxia,Ma Zhixin,Xu Yu,Huang ShuJuan,Li Chenying,Zhou Yile,Jin Jie
Funder
National Natural Science Foundation of China
Zhejiang Provincial Key Innovation Team
National Key Technology R&D Program
Subject
Pharmacology,General Medicine
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center;Current Medical Science;2023-12
2. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis;Cancer Chemotherapy and Pharmacology;2023-11-03
3. A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation;Medical Oncology;2023-01-10
4. In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia;Pathogenesis and Treatment of Leukemia;2023
5. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression;Journal of Zhejiang University-SCIENCE B;2022-08